121 results
S-8
EX-99.4
ITCI
Intra-Cellular Therapies Inc
25 Jun 24
Registration of securities for employees
4:28pm
of your Continuous Service for any reason other than Cause, your Disability or your death, except as otherwise provided in Section 7(d) below; provided … Disability, except as otherwise provided in Section 7(d) below;
(d) eighteen months after your death if you die either (i) during your Continuous
S-8
EX-99.7
ITCI
Intra-Cellular Therapies Inc
25 Jun 24
Registration of securities for employees
4:28pm
of the Participant’s death, or (c) such earlier date as permitted under Section 409A of the Code without the imposition of adverse taxation. Upon
S-8
EX-99.3
ITCI
Intra-Cellular Therapies Inc
25 Jun 24
Registration of securities for employees
4:28pm
) three months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death, except as otherwise … of your Continuous Service due to your Disability, except as otherwise provided in Section 7(d) below;
(d) eighteen months after your death if you die
S-8
EX-99.5
ITCI
Intra-Cellular Therapies Inc
25 Jun 24
Registration of securities for employees
4:28pm
that is six (6) months and one (1) day after the date of such separation from service, (b) the date of the Participant’s death, or (c) such earlier date
S-8
EX-99.6
ITCI
Intra-Cellular Therapies Inc
25 Jun 24
Registration of securities for employees
4:28pm
from service, (b) the date of the Participant’s death, or (c) such earlier date as permitted under Section 409A of the Code without the imposition
S-8
EX-99.2
6qh7u9r1907wras
25 Jun 24
Registration of securities for employees
4:28pm
8-K
EX-10.1
z8pn k6h9w
18 Jun 24
Departure of Directors or Certain Officers
4:16pm
8-K
EX-99.1
4652sa 6kqsw8m4
18 Jun 24
Other Events
7:37am
8-K
EX-99.1
82u pc31d6g7hw
7 May 24
Intra-cellular Therapies Reports First Quarter 2024 Financial Results
7:40am
8-K
EX-1.1
qwi02 2oy68w
18 Apr 24
Entry into a Material Definitive Agreement
5:25pm
424B5
ywi777g
18 Apr 24
Prospectus supplement for primary offering
5:23pm
424B5
8zd6xod 390gyl
16 Apr 24
Prospectus supplement for primary offering
4:37pm
8-K
EX-99.1
3ewqmq11 uvzpaso
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
8-K
EX-99.1
f20 h6i71n8qf
22 Feb 24
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
7:39am
8-K
EX-99.1
sz2tvxgna044w6gn3
2 Nov 23
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
8:01am
8-K
EX-99.1
rdstxqy 8gh
3 Aug 23
Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
7:39am
8-K
EX-99.1
srgwub
4 May 23
Intra-cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:37am